Tirzepatide
Metabolic
Also known as: Mounjaro, LY3298176
A dual GIP/GLP-1 receptor agonist providing superior glycemic control and weight loss.
- Dose in studies
- 2.5-15 mg weekly (titrate up slowly)
- Frequency
- Once weekly, same day each week
- Cycle length
- Continuous under medical supervision
- Half-life
- 5 days
- Research level
- 5/5 – Extensively researched
Frequently asked questions about Tirzepatide
What is Tirzepatide?
A dual GIP/GLP-1 receptor agonist providing superior glycemic control and weight loss.
What is the half-life of Tirzepatide?
The half-life of Tirzepatide is 5 days.
What dosage of Tirzepatide has been studied?
Described in research: 2.5-15 mg weekly (titrate up slowly), frequency: Once weekly, same day each week. This is not a medical recommendation.
How long is a Tirzepatide cycle?
Typical cycle length in studies: Continuous under medical supervision.
What are the side effects of Tirzepatide?
Nausea: The most reported side effect, affecting ~25% of users. Typically worst during dose escalation. Taking with a small meal and slow titration minimizes severity. Usually resolves by week 4-6. · Decreased appetite: Intended therapeutic effect but can be pronounced. Ensure adequate protein intake (1.2-1.6g/kg) to prevent muscle loss. · Diarrhea: Reported by ~15% of users, especially during…
How well researched is Tirzepatide?
Extensively researched (5/5). Approved, large randomised trials and robust long-term safety data.